Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,248 across all filing types
Latest filing 2019-05-18 Annual Report
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Limited dated May 18, 2019, reporting the outcome of a Board Meeting. It includes approval of audited standalone and consolidated financial statements for the quarter and year ended March 31, 2019, along with the audit report. It also mentions the declaration of an unmodified opinion on the annual audited financial results, recommendation of dividend, scheduling of the 33rd Annual General Meeting, book closure dates, reappointment of directors, reappointment of auditors, adoption of various policies, and approval of banking facilities. The document contains substantive financial data and detailed corporate governance and management decisions. It is not merely an announcement of a report but includes actual financial results and audit opinions. Therefore, this document is best classified as an Annual Report (10-K equivalent) or a comprehensive financial results announcement. Given the presence of audited financial statements and audit report approval, the classification as Annual Report (10-K) is appropriate. FY 2019
2019-05-18 English
We would like to inform you that Board Meeting of the Company was held today i.e. on Saturday, May 18, 2019 at registered office of the Company. In pursuant to Regulation 30 and 33 of Securities ....
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Limited dated May 18, 2019, reporting the outcome of a Board Meeting. It includes approval of audited standalone and consolidated financial statements for the quarter and year ended March 31, 2019, along with the audit report. It also mentions declaration of dividend, AGM date, book closure dates, reappointment of directors, reappointment of auditors, adoption of various policies, and approval of banking facilities. The document contains substantive financial data and detailed corporate governance and management decisions. It is not merely an announcement of a report but includes actual financial results and audit opinions. Therefore, this document is best classified as an Interim / Quarterly Report (IR) because it covers quarterly and annual financial results with audit reports, and includes comprehensive financial data and corporate updates. The presence of both quarterly and annual data and audit reports supports classification as IR rather than just an Earnings Release or Annual Report. Confidence is high due to the detailed financial tables and regulatory references.
2019-05-18 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for May 18, 2019, to consider and approve the audited standalone and consolidated financial statements and results for the quarter and financial year ended March 31, 2019, and to recommend a dividend if any. It includes a newspaper advertisement of the notice of the Board Meeting. The document does not contain the financial statements or results themselves but is an announcement related to the meeting where these will be approved. Therefore, it is not the Annual Report (10-K) or Interim Report (IR) itself, but rather a Regulatory Filing (RNS) announcing the Board Meeting and related agenda. The document length is 15,000 characters, but the content is primarily an announcement, not the report itself.
2019-05-16 English
Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Saturday, May 18, 2019 at the registered office of the Company ....
Regulatory Filings Classification · 95% confidence The document is a notice regarding a Board Meeting scheduled for May 18, 2019, where the audited standalone and consolidated financial statements and results for the quarter and financial year ended March 31, 2019, will be considered and approved. It also mentions the recommendation of a dividend for the financial year ended March 31, 2019. The document is a newspaper advertisement of the notice of the Board Meeting and does not contain the financial statements or results themselves. It is an announcement related to the upcoming Board Meeting and the agenda items to be discussed, not the actual report or financial data. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and notice rather than a full financial report or other specific filing type.
2019-05-16 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is extremely short (384 characters) and contains only addresses and stock exchange listing department references without any substantive content, financial data, or report details. It does not contain any financial statements, management discussion, or regulatory certifications. It appears to be a brief communication or cover letter rather than a full report or announcement. Given the lack of content and the nature of the text, it best fits the category of Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories.
2019-05-10 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2019 ,inter alia, to consider and approve the following: a) ....
Board/Management Information Classification · 95% confidence The document is a notification titled 'Intimation of Board Meeting' dated May 10, 2019, informing about an upcoming Board Meeting scheduled for May 18, 2019. The purpose of the meeting includes consideration and approval of audited financial statements and results for the quarter and financial year ended March 31, 2019, and recommendation of dividend. The document references regulatory compliance under SEBI regulations and insider trading rules. The content is an announcement of a board meeting and its agenda, not the actual financial report or results. The document length is 3767 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Board/Management Information filing (MANG), as it relates to board meeting notification and management information about upcoming decisions.
2019-05-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.